News,  Webinars,  Publications


18 May 2018

Sanoosa will be present at the Bio 2018 International Convention in Boston, MA, on June 4-7, 2018.  Sanoosa has developed a small molecule drug discovery & design platform that utilises its proprietary forecast-software to replace most of wet chemistry. Our technology comprises agile process structures and is focused on difficult to drug disease targets, like protein-protein interactions and protein surfaces. Sanoosa’s Founders will meet interested partners and potential collaborators at several one-on-one meetings in Boston.

25 March 2018

Sanoosa is collaborating with JATTECHNOLOGY to develop enhanced analysis tools for drug design applications.  As part of our support for the research community JATTECHNOLOGY and Sanoosa today deposited LigandViewer for macOS to the Mac App Store

20 September 2017

Working closely with a large pharma partner, Sanoosa received promising test results for Sanoosa’s Nav1.7 ion-channel inhibitor program and for another undisclosed target. The results for Nav1.7 delivered a novel scaffold which is now the basis to computationally design compounds for Nav1.7 inhibitors with higher specificity and selectivity.

16 May 2017

Changing Habits Pty Ltd has launched Sanoosa’s products for preventing inflammation  and for preventing hypercholesterolemia  into the Australian market. Concurrently, Changing Habits makes the products also available to its overseas customers. 

16 May 2017

A NATURAL APPROACH - MERGING SCIENCE & NATURE: Changing Habits / Sanoosa interview on disease prevention: .

23 November 2016

Sanoosa Pty Ltd. enters a licensing agreement with Sunshine Coast /Australia based Changing Habits Pty Ltd to commercialize Sanoosa’s products for preventing inflammation  and for preventing hypercholesterolemia .


Coming soon:  Small Molecule Protein-Protein Interaction Inhibitors

Stay tuned for a FREE webinar with an introduction to new developments in drug discovery where computational methods will play a bigger if not a dominant role in the early stages in drug development in the future. 

Small Molecule Protein-Protein-interaction inhibitors (smPPII) are an emerging drug class which recently has entered the discussion of drug discovery and R&D productivity. By targeting “hot spots” on the protein surface, small molecules have shown to be able to disrupt effectively protein-protein interactions. This approach seem to decrease risks for later drug development stages. 

Computational methods applied for the discovery and design of appropriate smPPII compounds have proven to deliver better quality in significant shorter time and substantial lower cost. 

In combination, computational discovery and design methods and smPPIIs provide a double de-risk strategy in drug development and create a quantum leap in R&D productivity. 

This webinar discusses our experience in this field and the implications on the early drug discovery phase in particular.

Selected Publications:

  • First small molecule protein-protein interaction inhibitor to prevent PSCK9 binding to LDL receptor:   WO2018165718A1, Treutlein H.R., Zeng J., Dixon I., James I., Palmer J. T. , Heterocyclic inhibitors of PCSK9. Patent published 20/09/2018.
  • Currier MA, Stehn JR, Swain A, …, Treutlein HR, et al. Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy With Microtubule Drugs. Molecular Cancer Therapeutics. May 2017. doi:10.1158/1535-7163.MCT-16-0873.
  • Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein HR, et al. A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Research. 2013 Aug 15;73(16):5169–82. 
  • Burns CJ, Bourke DG, Andrau L, Xianyong Bu, Charman SA, Donohue AC, Fantino E, Farrugia M, Feutrill JT,  Joffe M, Kling MR, Kurek M, Nero TL, Nguyen T, Palmer JT, Phillips I, Shackleford DM, Sikanyika H, Styles M, Su S, Treutlein HR, Zeng J, Wilks AF, Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorganic & Medicinal Chemistry Letters, 2009. 
  • First paper on the successful design of a protein-protein interaction inhibitor: Zeng J, Thao Vuong-Nhen, Anna Zorzet, Bruno Catimel, Ed. Nice, Antony W. Burgess, Treutlein HR, Protein Engineering 14 (2001) 39, “Computational combinatorial design of short peptides that interfere with Ras-Raf association in vitro”.
  • This paper describes our early version of the MFMD method: Zeng J., Treutlein HR, A method for computational combinatorial peptide design of inhibitors of Ras. Protein Engineering 12, 457-468, 1999. 
  • Groenen L.C., Walker F., Burgess A.W., Treutlein HR. A Model for the Activation of the Epidermal Growth Factor Receptor Kinase: Involvement of an Asymmetric Dimer? Biochemistry 36 (13), 3826-3836, 1997. 
  • Treutlein HR, Schulten K, Brunger AT, Karplus M, Deisenhofer J, Michel H. Chromophore-protein interactions and the function of the photosynthetic reaction center: A molecular dynamics study, PNAS 89, 75-79, 1992.
  • Treutlein HR, Lemmon MA, Engelman DM, Brunger AT. The Glycophorin A transmembrane domain dimer: Sequence-specific propensity for a right-handed supercoil of helices.  Biochemistry 31, 12726-12733, 1992.

A complete list is available from Herbert's ORCID site:

This website makes use of cookies. Please see our privacy policy for details.

This website makes use of cookies. Please see our privacy policy for details.